17 Products
A large Asian conglomerate was working to develop their asset portfolio in Cell Imaging and Analysis, and was interested to assess the market scenario of software based devices in the Cell Analysis and Cell Observation segment, such as HCS, Cell Analyzers, Flow Cytometers etc., to understand the past and forecasted market...
17 Products
A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.
17 Products
A CDMO client based in Europe, involved DelveInsight to provide in-depth competitor assessment of companies active in the pharma CDMO area, in order to understand effective landscaping and conduct strategic decision-making for gaining competitive advantage.
17 Products
A large pharma client was working to develop their API and FD, and was interested to assess CDMO companies and their capabilities in this domain to provide benchmarking of the best company for outsourcing their project.
17 Products
A mid-sized EU-based firm roped in DelveInsight for evaluation of the developmental pipeline of COVID-19 to assess the competitors across the clinical development pipeline. They intended to recognize and analyze the emerging therapies, key competitors and study the landscape based on the mechanism of action...
17 Products
One of the regular Europe-based clients wished to evaluate a long-term research partner who can timely deliver valuable competitive insights to support the clinical, commercial, and launch strategies of their novel class of...
.jpg)
17 Products
A global pharmaceutical company desired a web-based, robust and simplified, and user-friendly interactive dashboard that encompasses launch timelines, study start date and primary completion date, Primary and secondary outcomes, Trial locations, any regulatory designation assigned to products, developing companies, Their partners, technology being used and others to help..
17 Products
A global pharmaceutical company aimed to monitor the performances of its wide variety of newly launched oncology products based on Lead and Lag KPIs on a monthly, quarterly, and yearly basis in Locally operating countries (LOCs).
17 Products
A global pharmaceutical company wished to evaluate the market value of an asset obtained by acquiring a mid-cap company. The new class of drug showed the potential in targeting multiple tumors in combination with their in-house immune checkpoint inhibitor (CPI). The assessment formed the basis of their decision.
17 Products
A client based in the US wanted the epidemiology assessment exercise to understand the percentage of solid organ transplant recipients who develop Cutaneous Squamous Cell Carcinoma (cSCC) for 15 countries, including the US, key European countries, and key countries from APAC
17 Products
European-based Medical Device Company wanted to understand the complete landscape in regard to current available Patient Pool, Devices Market Size and Competitor Share for Patent Foramen Ovale (PFO) in the EU to assess potential value-based market size of Patent Foramen Ovale for aligning business opportunities in this segment...
17 Products
A large medical device client, based in the United States, with capabilities in drug delivery medical devices, involved DelveInsight to assess the potential risks and benefits of a merger being evaluated to further the goal of becoming market leaders in the niche area of drug delivery through a novel technology (dissolvable microneedle technology) for drug delivery.
17 Products
A medium pharmaceutical client with capabilities in novel formulations was involved in a deal with a manufacturing company for commercial-scale manufacturing of the client’s therapies. The client involved DelveInsight to conduct a comprehensive appraisal of the partner’s business, prior to the closing of the deal between the two parties.
17 Products
A large pharmaceutical client based in Europe involved DelveInsight to identify patient advocacy strategies of companies operating in the Pharma sector of the European Union, to benchmark their efforts against their competitors.
17 Products
A large client based in USA, involved in drug delivery devices, with effective marketing and commercialization presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products.
17 Products
A medium pharmaceutical client based in United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe through Competitive Assessment of their EU based competitors in the same area of interest. They wished to identify manufacturing sites, logistic operations, distribution network, salesforce assessment and their sales targets.
17 Products
A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing and commercialization presence in Europe, wanted to assess the launch readiness of competitors involved in the same arena for strategic positioning of their own product.
17 Products
A large pharma client was working to develop their cyclophosphamide API and FD, and was interested to assess competitive products in the same domain and area to provide benchmarking of their asset in comparison to their competitors.
17 Products
A mid-sized pharma client was working to develop their asset portfolio, and was interested to assess best possible asset for atrial fibrillation for future development and licensing needs The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through possible licensing collaborations.
17 Products
A medium pharmaceutical client based in the US, with innovative formulations to treat Head and Neck Cancer, involved DelveInsight to identify a co-development partner, for the US and European region.
17 Products
A large client based in Europe, involved in Dermatology arena with a market-ready product, aimed to assess the Indian Regulatory Scenario to successfully file the product in CDSCO. They wished to identify the guidelines of approval, assess the documentation needed in India, and need for conducting clinical trials and post-market surveillance processes.
17 Products
A small-Pharma client based in Israel involved DelveInsight to manage their portfolio of candidates indicated for various infectious diseases. The client provided DelveInsight with the task of assessing the best strategic direction for each asset through extensive market research analysis, for development for US and EU regions.
17 Products
A medium pharmaceutical client based in the US, with innovative formulations to treat Head and Neck Cancer, involved DelveInsight to identify a co-development partner, for the US and European region.
17 Products
A mid-Pharma client based in India involved DelveInsight to assist in gathering and analyzing congress abstracts and literature review from various congresses for Parkinson’s disease. DelveInsight was involved to support the assessment of the R&D landscape through via secondary and primary research to form intelligent research outcomes.
17 Products
A large medical device client, based in the United States with capabilities in drug delivery medical devices, involved DelveInsight to assess the potential risks and benefits of a merger being evaluated to further the goal of becoming market leaders in the niche area of drug delivery through novel technology.
17 Products
A medium pharmaceutical client based in the United States with capabilities in cancer immunotherapy domain involved DelveInsight to analyze current pipeline activity of T-Cell Receptor (TCR) products for cancer treatment. They wished to identify currently active T-Cell Receptor (TCR) products in research and development for cancer treatment.
17 Products
A large Pharmaceutical company, headquartered in the US, wanted DelveInsight to support them by providing a detailed conference coverage of the oncology drug for the indication HER2 negative breast cancer published during ASCO 2022, including the product description, research and developmental activities, product milestones, future plans and KOL insights.
17 Products
To support the client in congress/ conference coverage of the key/selected assets in Oncology domain presented at AACR 2022, ASCO 2022, and ESMO 2022, by comprehensive pre-conference planning, effective intelligence gathering during the conference, and insightful post-conference reports
17 Products
A mid-sized European Pharmaceutical Company, wanted DelveInsight to support them by providing a detailed ATS 2022 conference coverage of the assets of their interest in the Asthma and COPD disease area, including the emerging product analysis, developmental activities, safety and efficacy data, product milestones, future plans and KOL insights.
17 Products
A large US base Pharma Company, wanted DelveInsight to support them by providing a detailed CAR-TCR Summit coverage of novel CAR-T Cell Therapies for the B-Cell Malignancies, including the emerging product analysis, developmental activities, safety and efficacy data, product milestones, future plans and KOL insights.
17 Products
Idiopathic Pulmonary Fibrosis (IPF) is the archetypical progressive fibrotic interstitial lung disease (ILD). As the morbidity and mortality rates associated with IPF remain high, prompt treatment of IPF is critical to safeguard patients’ lung function, reduce the risk of acute exacerbations, and improve outcomes.
